Save time and jump to the most important pieces.
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
4 - Societal CDMO, Inc. (0001588972) (Issuer)
CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20
CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATER, Fla. and GAINESVILLE, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has entered into a definitive agreement with CoreRx, Inc. ("CoreRx") under which CoreR
SC 13D/A - Societal CDMO, Inc. (0001588972) (Subject)
SC 13G - Societal CDMO, Inc. (0001588972) (Subject)
SC 13D - Societal CDMO, Inc. (0001588972) (Subject)
15-12G - Societal CDMO, Inc. (0001588972) (Filer)
EFFECT - Societal CDMO, Inc. (0001588972) (Filer)
EFFECT - Societal CDMO, Inc. (0001588972) (Filer)
CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the MergerCoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 20
CoreRx, Inc. ("CoreRx") today announced that it has completed its acquisition of Societal CDMO, Inc. ("Societal CDMO") (NASDAQ:SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics. The Offer and the Merger CoreRx's tender offer to acquire all of the issued and outstanding shares of common stock (the "Shares") of Societal CDMO, at a purchase price of $1.10 per Share, in cash, without interest and less any applicable tax withholding, expired as scheduled one minute following 11:59 p.m., Eastern Time, on April 5, 2024 and was not further extended. The depositary an
Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone KANSAS CITY, Kan., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update. Highlights include
SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Matt Arens to the company's board of directors. Mr. Arens has more than 25 years of experience as a successful investment professional identifying innovative life science companies with high growth potential. For the past 15 years, he solely has managed dedicated health care portfolios. Mr. Arens currently serves as chief executive officer and senior po
SAN DIEGO and GAINESVILLE, Ga., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Elena Cant to the company's board of directors. Ms. Cant has more than 20 years of diverse business experience ranging across various functions including corporate development, business operations and strategy, marketing, commercial, manufacturing, and research and development. She has an impressive track record of establishing and growing functional groups,
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.3% on Thursday. The Dow traded down 0.08% to 38,919.26 while the NASDAQ rose 0.53% to 16,032.35. The S&P 500 also rose, gaining, 0.30% to 5,084.84. Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Real estate shares rose by 1.2% on Thursday. In trading on Thursday, health care shares fell by 0.6%. Top Headline Shares of Hayward Holdings, Inc. (NYSE:HAYW) surged over 17% on Thursday after the company reported better-than-expected fourth-quarter results. Hayward Holdings posted adjusted earnings of 20 cents per share, beating mar
Shares of Butterfly Network, Inc. (NASDAQ:BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company’s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million. Butterfly Network shares dipped 21.7% to $1.1588 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Enveric Biosciences, Inc. (NASDAQ:ENVB) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to purs
Gainers Societal CDMO (NASDAQ:SCTL) stock rose 132.6% to $1.07 during Thursday's regular session. The company's market cap stands at $112.1 million. Enveric Biosciences (NASDAQ:ENVB) shares increased by 132.25% to $1.93. The market value of their outstanding shares is at $5.2 million. Envoy Medical (NASDAQ:COCH) stock rose 47.29% to $5.17. The market value of their outstanding shares is at $101.0 million. Tivic Health Systems (NASDAQ:TIVC) shares moved upwards by 30.39% to $1.63. The market value of their outstanding shares is at $2.3 million. Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 29.68% to $7.34. The company's market cap stands at $644.5 million. The company's, Q4 e